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ABSTRACT 
Depression is treated by a great variety of antidepressant treatments. SSRIs (such as fluoxetine) 
are well known: it is, however, sure that further progress is needed and the search for 
antidepressants with other mechanisms of action (such as tianeptine) or different efficacy is still 
of interest. A multinational study compared tianeptine with fluoxetine in 387 patients with 
Depressive Episode, or Recurrent Depressive Disorder, or Bipolar Affective Disorder (ICD-10), in 
a double-blind parallel group design. They were treated for six weeks. At inclusion, no significant 
difference between groups was shown. Final MADRS scores were 15.7 and 15.8 with tianeptine 
and fluoxetine, respectively (ITT population) (p = 0.944). MADRS responders were 58% and 
56% with tianeptine and fluoxetine, respectively (p = 0.710). No statistical difference was 
observed for the other efficacy parameters. Thirty-six withdrawals occurred in each group, 
without any difference for the reasons of discontinuation. There was no major difference 
between groups for the other safety parameters. In this study, both tianeptine and fluoxetine 
exhibited a good efficacy and safety. 
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Tianeptine is an antidepressant which differs from the conventional antidepressants by its 
unique property of increasing 5HT uptake in the synaptic cleft. In pharmacological studies, its 
antidepressive activity has been shown using the classical screening tests of antagonism of 
reserpine-like compounds, rat behavioural despair (Porsolt's test) and aggressive behaviour 
induced by isolation in mice (Poignant, 1981; Mocaër, 1988). It has been demonstrated that 
tianeptine was active in the bulbectomized rat model of depression (Kelly and Leonard, 1990) 
and in stress models of depression such as immobilisation stress (Whitton et al., 1991) and 
inescapable shocks in the learned helplessness paradigm (Thiébot et al., 1992).  
Neurochemistry studies have shown that tianeptine increases serotonin uptake in rat brain 
(Mennini et al., 1987), and rat (Kato and Weitsch, 1988) and human platelets (Renaud et al., 
1988; Chamba et al., 1991) after acute and chronic administration. 
Tianeptine is currently administered three times a day (12.5 mg X 3/day). Its antidepressant 
efficacy is comparable to those of imipramine and amitriptyline (Ostaptzeff, 1981; Weiss et al., 
1981; Lôo et al., 1988; Guelfi et al., 1989; Guelfi, 1992; Invernizzi et al., 1994). Until recently, 
most of comparative studies with tianeptine were performed versus usual tricyclics or placebo. 
However, a comparative study versus fluoxetine has already been performed (Alby et al., 1993). 
This study was carried out in 206 depressed patients: it showed no difference between 
tianeptine and fluoxetine in respect of their antidepressive efficacy. Some limitations in data 
interpretation made it necessary to conduct a second trial, which is presented in this paper. 
Further comments on the first study will be made in the discussion section. 
Tianeptine has been shown to be effective in patients suffering from depression alone or 
associated with anxiety or alcoholism. Its safety has been confirmed in more than 3000 patients 
treated in open and controlled studies for one month to one year (Delalleau et al., 1988; Chapuy 
et al., 1991; Guelfi et al., 1992; Lôo et al., 1990, 1992). The comparison studies showed a better 
safety profile in comparison to trycyclic antidepressants: lower rate of adverse events, fewer 
atropinic or cardiovascular side-effects, fewer sedative properties. 
Adverse effects are infrequent and mostly mild: digestive disorders (such as abdominal pain, 
nausea, vomiting, constipation, dry mouth), insomnia, drowsiness, headache and tachycardia. 
Fluoxetine is a selective serotonin reuptake inhibitor which was demonstrated to be effective in 
the treatment of major depressive episode (Montgomery, 1995). Its adverse effects are mostly 
mild and rare: tremors, insomnia, headache, drowsiness, digestive disorders (nausea, diarrhoea, 
dry mouth), rarely cutaneous disorders and cardiovascular disorders (bradycardia). 
The aim of the current study was to compare the efficacy and safety of tianeptine with those of 
fluoxetine, an SSRI antidepressant, in the treatment of depressive disorders. 
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This study was a multicentre, international, phase III double-blind controlled trial. All patients 
were included between October 1995 and November 1996. Ten countries participated in the 
trial: Austria, Belgium, Brazil, France, Germany, Italy, the Netherlands, Portugal, Spain and 
United Kingdom. In each country, the study protocol was submitted to the relevant Ethics 
Committee for approval: the study began in each centre only after receiving the written approval 
of the Ethics Committee on which it depended. 
In each country, the training of the investigators for the rating of the scales used in this trial was 
made by the use of video tapes of depressed patients. 
Patients were treated in a parallel group design either with tianeptine (12.5 mg t.i.d., at 8 am, 
noon and 8 pm) or with fluoxetine (20 mg once a day at 8 am, then placebo at noon and 8 pm) 
for 42 days, after a one-week run-in placebo period. The aim of the placebo pre-inclusion week 
was to exclude rapid placebo-responders. 
INCLUSION CRITERIA 
Men and women, aged from 18 to 65 years, in- or out- patients were selected if they met the 
following inclusion criteria: Depressive episode, Recurrent depressive disorder or Bipolar 
affective disorder (depressed) according to the ICD-10 classification (moderate or severe 
episode, with or without somatic syndrome, without psychotic symptoms); having a MADRS 
(Montgomery and Asberg, 1979) score ≥ 25 points, and requiring an antidepressant treatment. 
All patients freely gave their written informed consent to participate in the study. 
EXCLUSION CRITERIA 
The patients who were not allowed to participate in the study had other types of depression 
(especially dysthymia and double depression), a severe risk of suicide, an acute or chronic 
psychosis or had failed to respond to two antidepressants for the current depressive episode. 
Other exclusion criteria were previous history of drug abuse or dependence, severe somatic 
diseases in evolution, and current treatment with barbiturates, buspirone, thymoregulators, 
antiepileptic drugs. Diazepam was forbidden because of potential interaction with fluoxetine: 
lorazepam and alprazolam were not allowed as some publications have shown that they may 
possess some antidepressive properties. 
CONCOMITANT TREATMENTS 
No concomitant psychotropic medication was allowed, but if the patient had used a 
benzodiazepine (except those mentioned under Exclusion Criteria) for at least one month before 
the trial, he/she was to continue taking it. If a patient without a benzodiazepine needed an 
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anxiolytic treatment during the trial, he could only receive clorazepate (maximum dosage: 30 
mg/day) or oxazepam (maximum dosage: 60 mg/ day). The prescription of somatic treatments 
was permitted provided they did not interfere with depression. 
ASSESSMENTS 
Patients were assessed at selection (D-7), at the inclusion (D1) and then during the study at D7, 
D14, D28 and D42. 
At the selection visit (D-7), a complete psychiatric interview (history of depression and of the 
present depressive episode, check for inclusion and exclusion criteria) and a complete physical 
examination were performed. Laboratory parameters with haematology (RBC, WBC, 
haemoglobin, differential blood count, platelets, haematocrit) and biochemistry (glucose, 
creatinine, ALAT, ASAT, ÎGT, alkaline phosphatase, total bilirubin) were also measured. 
At D1, patients were definitively included if they still fulfilled the inclusion criteria, if the 
decrease in the MADRS score was lower than 30%, and this score remained higher than 25 
points. 
At each visit, D7, D14, D28 and D42, the severity of the depressive symptomatology was 
assessed with the MADRS and CGI (Clinical Global Impression) scale. In order to document the 
evolution of the somatic complaints of the patients and to search for any adverse events, the 
AMDP5 scale (Bobon, 1981) was used at each evaluation. 
At the last visit (D42), a medical examination was performed and laboratory parameters were 
also measured. 
Compliance was measured at each visit by the count of the number of capsules brought back by 
the patients. 
STATISTICAL ANALYSIS 
The main efficacy criterion was the final MADRS global score. The secondary efficacy criteria 
were a decrease of 50% in MADRS global score (responder patients), and the CGI scores. 
The safety was evaluated with emergent adverse events, somatic complaints at each visit and 
with vital signs and biological parameters at D-7 and D42. 
Student's t test for independent samples was performed for quantitative variables and a Fisher's 
exact test for qualitative variables. Differences between the two groups were tested with a 
Student's t test. The change over the time comparison was performed with a two-way analysis of 
variance (group X time) with repeated measures. Delay of responses were studied in terms of 
survival curves according to the Kaplan-Meier method. Survival curves were compared using the 
log-rank test. The main analysis was performed on the intention-to-treat (ITT) population using 
the last observation carried forward method and secondary analyses on the per-protocol (PP) 
population. 
Published in : Human Psychopharmacology (2001), vol. 16, suppl. 1, pp. S31–S38 
DOI:10.1002/hup.268 




The minimum number of patients for the study was 300; it was calculated on the basis of a 
difference of 4 points in final MADRS scores between treatment groups, with α risk= 5%, β 
risk= 10%, and a standard deviation of 10. 
All analyses were performed using SAS V6.09 software. For all statistical tests, the type I error 
threshold was set at 5%. 
Results 
DESCRIPTION OF THE POPULATION 
Three hundred and eighty-seven patients were randomized (191 to the tianeptine group and 
196 to the fluoxetine group). The ITT population was madeup of 381 patients (187 in the 
tianeptine group and 194 in the fluoxetine group); six patients had baseline measurements and 
no evaluation on treatment, and were therefore excluded from the intention-to-treat analysis. 
The PP population (patients who completed the study duration without major deviation from 
the protocol) represented 266 patients (131 in the tianeptine group and 135 in the fluoxetine 
group). 
One hundred and ninety-seven patients (51%) were included in France, 61 patients (16%) in 
Spain, 45 patients (12%) in Brazil and the remaining 84 patients in Belgium, United Kingdom, 
Austria, Portugal, Germany, Italy and the Netherlands. No group X country effect was observed 
at inclusion or at the end of the treatment. 
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE PATIENTS 
At inclusion, no significant differences appeared between the two groups. 
Table 1 presents the demographic and clinical characteristics of the included patients. The mean 
age was 41.8 ± 11.0 years in the tianeptine group and 41.0 ± 11.4 in the fluoxetine group. One 
hundred and thirty-five patients (72%) and 147 patients (76%) respectively were women. 
Thirty-two patients in each group were hospitalized at inclusion. 
In the tianeptine group, 79 (42%) patients presented a depressive episode, 106 (57%) a 
recurrent depressive disorder and 2 (1%) a bipolar disorder. In the fluoxetine group, 73 (38%) 
presented a depressive episode, 121 (62%) a recurrent depressive episode and none a bipolar 
disorder. These differences were not significant (p = 0.374). 
The severity of the depression was moderate for 128 (68%) patients in the tianeptine group and 
126 (65%) in the fluoxetine group; it was severe for 59 (32%) patients in the tianeptine group 
and 68 (35%) in the fluoxetine group. Eighty-five (45%) patients in the tianeptine group and 92 
(47%) in the fluoxetine group resented a somatic syndrome (p = 0.778). The 179 patients of the 
randomized population who presented a somatic syndrome had the following characteristics: 
they were more frequently hospitalised than those who had no somatic syndrome (22.4% vs 
11.5%) and were more severely depressed (MADRS global score 33.3 ± 5.2 vs 30.9 ± 4.5). Sixty-
eight patients with severe depression (53%) had no somatic syndrome. 
Published in : Human Psychopharmacology (2001), vol. 16, suppl. 1, pp. S31–S38 
DOI:10.1002/hup.268 




It was the first depressive episode for 74 (40%) patients in the tianeptine group and for 66 
(34%) patients in the fluoxetine group. The mean duration of the current episode was 6.8 ± 14.4 
months in the tianeptine group and 7.2 ± 16.4 months in the fluoxetine group (p = 0.835). 
Forty-four of 110 patients (39%) in the tianeptine group and 47/126 (37%) patients in the 
fluoxetine group had a history of three or more depressive episodes. The mean duration since 
the first depressive episode was 124.6 ± 111 months in the tianeptine group and 114.0 ± 109 
months in the fluoxetine group (p = 0.455). Sixty-three (34%) patients in the tianeptine group 
and 56 (29%) in the fluoxetine group had a family history of depression. 
The initial MADRS global score was 32.12 ± 4.80 points in the tianeptine group and of 31.93 ± 
5.13 in the fluoxetine group (p = 0.702). The first item of the CGI (severity of illness) was 4.64 ± 
0.69 in the tianeptine group and 4.69 ± 0.79 in the fluoxetine group (p = 0.476). 
 
Table 1. Demographic characteristics of the patients (ITT population) 
 Tianeptine 
n = 187 
mean ± S.D. 
Fluoxetine 
n = 194 
mean ± S.D. 
p 
Sex    
Men 52 (28%) 47 (24%) 0.496 
Women 135 (72%) 147 (76%)  
Age (years) 41.8 ± 11.0 41.0 ± 11.4 0.465 
Weight (kg) 68.9 ± 15.9 68.5 ± 17.2 0.829 
Height (cm) 165.1 ± 8.5 164.2 ± 7.7  
Depressive episode 79 (42%) 73 (38%)  
Recurrent depression 106 (57%) 121 (62%) 0.374 
Bipolar disorder 2 (1%) 0  
Duration of the current 
episode (months) 
6.8 ± 14.4 7.2 ± 16.4 0.835 
Duration since the first 
episode (months) 
124.6 ± 110.7 114.0 ± 108.5 0.455 
First episode 75 (39%) 66 (34%)  
Three previous episodes or 
more 
43/110 (39%) 47/126 (37%)  
Family history of depression
  
63 (34%) 56 (29%)  
 
EFFICACY 
At the end of the treatment, in the ITT population the global score on the MADRS was 15.69 ± 
10.85 in the tianeptine group and 15.77 ± 11.19 in the fluoxetine group (p = 0.944). In the PP 
population the difference was not significant either (p = 0.967). The first item of the CGI 
(severity of illness) was 2.79 ± 1.44 in the tianeptine group and 2.75 ± 1.45 in the fluoxetine 
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group (p = 0.821). The second item of the CGI (global improvement) was 2.21 ± 1.33 in the 
tianeptine group and 2.22 ± 1.25 in the fluoxetine group (p = 0.984). The third item of the CGI 
(efficacy index) was 2.83 ± 1.24 in the tianeptine group and 2.79 ± 1.26 in the fluoxetine group 
(p = 0.719). 
Considering the time course of the MADRS scores in the PP population, the scores decreased 
significantly at each visit (p = 0.01) and for both groups the difference between D1 and D42 was 
highly significant (p = 0.001), but the difference was not significant between the two treatment 
groups (p = 0.418) (Table 2). Item 10 of the MADRS (suicidal thoughts) did not differ between 
the two groups in the ITT population at D42 (p = 0.709). 
The delay of response to treatment (log-rank test on survival curves) was not significantly 
different between the two groups (p = 0.722). At D42, in the ITT population, 109 (58%) patients 
in the tianeptine group and 109 (56%) patients in the fluoxetine group were responders (p = 
0.710): in the PP population 89 (68%) patients in the tianeptine group and 86 (64%) patients in 
the fluoxetine group (p = 0.550) were considered as responders to the treatment according to 
the MADRS score. The differences were not significant, but the percentage of responders was 
slightly higher in the tianeptine group. The analysis in survival curves did not show any 
difference between the two groups. 
The investigators considered the efficacy as good or excellent for 63% of the patients in each 
group (Figure 1). From the patients' point of view, 59% in the tianeptine group and 63.5% in the 
fluoxetine group considered that the treatment had good efficacy (Figure 2). 
 
Table 2. Evolution of MADRS score (PP population) 
PP 
population 
Tianeptine n = 131 
mean ± S.D. 
Fluoxetine n = 134 
mean ± S.D. 






D1 31.8 ± 4.60 30.99 ± 3.84    
D7 26.1 ± 6.78 26.40 ± 5.77    
D14 20.95 ± 7.58 21.11 ± 7.75 0.418 0.646 <0.001 
D28 16.36 ± 7.42 15.42 ± 8.07    
D42 12.85 ± 8.06 12.91 ± 8.12    
SAFETY 
No laboratory parameters of vital signs differed significantly throughout the trial in any group or 
between the two groups. 
During the trial, 40-45% of patients received a benzodiazepine treatment. This percentage was 
not different between groups and did not change during the study. 
At inclusion, the most common somatic complaints recorded using the AMDP5 scale were 
interruption of sleep (73%), difficulty falling asleep (67%), shortened duration of sleep (64%), 
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decreased appetite (59%) and decreased libido (58%). Most somatic complaints disappeared in 
both treatment groups: this improvement is likely to be secondary to the improvement in the 
depression of the patients. However, more patients complained of nausea, gastric discomfort, 
diarrhoea, palpitations, backache, chills and tremor with fluoxetine than with tianeptine. 
Conversely, more patients complained of shortened sleep, excessive thirst, cardiac pain and 
paraesthesia with tianeptine than with fluoxetine. 
Withdrawals were observed in 72 patients (36 patients in each group). The reasons were 
adverse events (15 and 16 patients for tianeptine and fluoxetine groups, respectively), inefficacy 
(12 and 8 patients for tianeptine and fluoxetine groups, respectively), non-medical reasons (8 
and 9 patients for tianeptine and fluoxetine groups, respectively), patients lost to follow-up (one 
patient in each group) and major deviation for 2 patients in the fluoxetine group. The serious 
adverse events with tianeptine were suicide attempts (3 cases), worsening of depression (3 
cases), arthralgia (1 case), malaise with dizziness (1 case), weight increase (1 case); 
furthermore one patient became pregnant. One of the suicide attempts was successful. The 
serious adverse events with fluoxetine were suicide attempts (3 cases), active plans for suicide 
(1 case), agitation (1 case), fall (1 case), eczema (1 case); furthermore one patient became 
pregnant. One of the patients who discontinued fluoxetine because of an adverse event fulfilled 
the criteria suggested by Sternbach (1991) for serotonin syndrome. 
The investigator considered the safety as satisfactory for 88% of the patients in the tianeptine 
group and for 86% in the fluoxetine group (Figure 3). From the patients' point of view, 86% and 
84% respectively judged the safety as satisfactory. 
One hundred and eighty-six patients in the tianeptine group and 190 patients in the fluoxetine 
group (out of a total of 376 patients, 97.2%) had good compliance. 
 
 
Figure 1. Global evaluation by the investigators 
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Figure 3. Global evaluation of the safety by the investigators 
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As mentioned in the Introduction, Alby et al. (1993) have already carried out a double-blind 
study comparing tianeptine and fluoxetine. This study was performed in 206 patients, 
presenting either a major depressive episode or dysthymia (DSM III-R), and somatic complaints 
(assessed by a check-list of somatic complaints). The combination of patients with different 
diagnoses in the same trial is always questionable and the analysis of separate subgroups of 
patients usually leads to a decrease in the power of the statistical analysis. Furthermore, the 
assessment tools which were used for measuring the efficacy could not permit a comparison of 
the results with those of other trials in the literature. 
The present study aimed to compare the efficacy and safety of tianeptine and fluoxetine in the 
treatment of depressive disorders diagnosed using ICD-10 criteria. The choice of ICD-10 for the 
inclusion of the patients was made because of the availability of this diagnostic system in the 
different languages of the different countries involved in this trial. Interestingly, while the ICD-
10 considers that most of the severe depressions should have a somatic syndrome, only 47% of 
these severely depressed patients had this syndrome in this trial; additional data from other 
studies may permit the significance of this diagnosis to be evaluated in the future. Some authors, 
Hiller et al. (1994), have already discussed the issue of the reliability of new diagnostic systems 
(ICD-10, DSM III and DSM III-R). Their conclusion was that the ICD- 10 diagnosis of 'depressive 
disorder' is in close relationship with that of 'major depression' of DSM III/ DSM III-R. Such a 
congruence had been criticised by Philipp et al. (1991) who suggested that ICD-10 did not bring 
a new major advance when compared with other diagnostic systems. Gross and Huber (1996) 
made a critical review of both ICD-10 and DSM IV systems and concluded that some aspects of 
these classifications of depressive or mood disorders may be questionable. Hiller et al. (1994) 
made an evaluation of the ICD-10 subcategories of depressive episode and recurrent depressive 
disorder and of the different severity categories (based on ICD-10) to see if both diagnoses could 
be clearly distinguished and this was not case for moderate and severe depressive syndromes. 
Some authors, Gross and Huber (1996), suggested that the somatic syndrome, as defined in ICD-
10 diagnostic system, may lack consistency, some items (early awakening, worsening in the 
morning, loss of interest, psychomotor retardation) being more valid than the others. However, 
other authors, Hamdi et al. (1997), evaluated the severity of depression using the HDRS in 
depressed patients with somatic syndrome versus those without this syndrome; in their study, 
the former were shown to be more severely depressed. This result is in agreement with those of 
Faravelli et al. (1996) and with our own results: the condition of the patients with somatic 
syndrome is more severe. Both tianeptine and fluoxetine showed their good efficacy and 
acceptability in the treatment of depressed patients. In fact, MADRS scores decreased 
significantly in both groups, even after seven days of treatment, and then continued to decrease 
progressively until the last evaluation at D42. It could have been interesting to have a placebo 
group in this study, so that the onset of action of both antidepressants can be documented by a 
statistically significant difference versus placebo. Forty to 45% of the patients received a 
benzodiazepine treatment during the study: this is in agreement with the everyday practice in 
some European countries; as the rates of prescription of benzodiazepines remained similar in 
both tianeptine and fluoxetine groups, this is not a major drawback for the conclusions of the 
study. Only 31 patients were withdrawn from the study because of adverse events. The 
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distribution was equal in both groups, 15 and 16 patients. Twenty patients were withdrawn 
because of inefficacy (12 and 8 patients, respectively). This is in favour of the good efficacy and 
safety of these two treatments. Especially, the safety of tianeptine, already shown in the previous 
studies, was confirmed. Thus, according to both the investigator's judgement and the patient's 
point of view the efficacy was considered as good or excellent in more than 60%, and the safety 
in more than 80%, of cases. 
This study has permitted the efficacy of tianeptine in treating ICD-10 depressive disorders to be 
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